OPINION
NEWS
REGIONS
WORLD
BUSINESS
SPORTS
ENTERTAINMENT
LIFESTYLE
THE SUNDAY TIMES
SPECIAL FEATURES
SPECIAL SECTIONS
TMT NEWSWIRE
FAST TIMES
LEGAL ADVICE
CAMPUS PRESS
VIDEOS
EXPATS & DIPLOMATS
PHOTOS
BUSINESS FORUM
PODCASTS
RESOURCES
WEATHER
MARKET OVERVIEW
CLASSIFIEDS
EXAM RESULTS
TMT DIGITAL EDITION
TMT CSI
TMT 126TH ANNIVERSARY
QUIZZES
GAMES
World
US congressional report slams FDA approval of Alzheimer's drug
By Agence France-Presse
Dec 31, 2022 12:03 am

Washington, United States: The US Food and Drug Administration's approval process for a controversial drug used to treat Alzheimer's was 'rife with irregularities,' a congressional report said Thursday (Friday in Manila).

An 18-month investigation into the FDA's green-lighting of the drug, Aduhelm, also criticized its manufacturer, biotechnology company Biogen.

Photo taken on Dec. 11, 2020 shows the US Food and Drug Administration building in Silver Spring, Maryland, the United States. XINHUA PHOTO

Related Articles

Prince William reflects on 'brutal' year as Kate returns to public life

Notre Dame bells ring out in Paris for first time since 2019 fire

Sacred cow: Coal-hungry India eyes bioenergy to cut carbon

Two dead, 12 missing after fishing boat sinks off South Korea

Venezuela signs defense, energy deals with Russia

Qantas plane returns to Australia airport due to 'engine failure,' sparks fire

SKorea holds missile drill after NKorea launches